NIH began clinical trial of hydroxychloroquine as potential therapy for COVID-19
On Apr. 9, 2020, the first participants were enrolled in the trial at Vanderbilt University Medical Center, Nashville, one of dozens of centers in the PETAL Network.
The blinded, placebo-controlled randomized clinical trial planned to enroll more than 500 adults who are currently hospitalized with COVID-19 or in an emergency department with anticipated hospitalization. All participants in the study received clinical care as indicated for their condition.
Those randomized to the experimental intervention also received hydroxychloroquine.
Tags:
Source: National Institutes of Health
Credit: Photo: Colorized scanning electron micrograph of an apoptotic cell (green) heavily infected with SARS-COV-2 virus particles (purple), isolated from a patient sample, Fort Detrick, Maryland. Courtesy: National Institute of Allergy and Infectious Diseases.
